the reversal of lymphopenia and treatment of multiply relapsed locally advanced or metastatic pancreatic cancer Over 100 participants have now received ANKTIVA in cancer prevention trial with goal to ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) ...

MPLX LP units are rated a hold due to fair valuation despite strong technicals and a high 7.7% distribution yield. MPLX has shown robust financial performance with consecutive earnings beats, solid ...

With the issuance of the permanent J-code in January 2025, ImmunityBio has seen increased sales momentum supporting a trend of increases month-over-month as well as quarter-over-quarter, with February ...

Cytokine fusion proteins, such as ANKTIVA, represent a novel class of biologics that improve immune responses by enhancing the therapeutic potential of cytokines and promoting lymphocyte infiltration ...